Unwanted effects of growth hormone excess in the adult

Journal of Pediatric Endocrinology and Metabolism

Volumn 9, Issue SUPPL., 1996, Pages 369-374

  Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ANIMAL MODEL; CAUSE OF DEATH; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG OVERDOSE; HUMAN; HYPERTROPHY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; RAT; RISK ASSESSMENT; TRANSGENIC ANIMAL;

ACROMEGALY; ANIMALS; GROWTH HORMONE; HUMANS;

EID: 0029762849     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Isaksson OGP, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987; 8: 426-438.
2. Shea BT, Hammer RE, Brinster RL. Growth allometry of the organs in giant transgenic mice. Endocrinology 1987; 121: 1924-1930.
3. Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Plamitter RD. Histopathology associated with elevated levels of growth hormone and insulin- like growth factor I in transgenic mice. Endocrinology 1989; 124: 40-48.
4. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39: 1-16.
5. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12: 71-79.
6. Richie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR. Ascertainment and natural history of treated acromegaly in Northern Ireland. The Ulster Med Journal 1990; 59: 55-62.
7. Bengtsson B, Eden S, Ernest I, Oden A, Sjorgren B. Epidemiology and long term survival in acromegaly. Acta Med Scand 1988; 223: 327-335.
8. Extabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: An epidemiological study. J Endocrinol Invest 1993; 16: 181-187.
9. Melmed S, Herman-Dowling R, Frohman LA, et al. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97: 468-473.
10. Herman-Bonert VS, Prager D, Melmed S. Growth hormone. In: Melmed S, ed. The Pituitary. Boston: Blackwell Science, 1994.
11. Lieberman SA, Huffman AR. Rheumatological and skeletal changes in acromegaly. Endocrinol Metab Clin 1992; 21: 615-631
12. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115: 527-532.
13. Grunstein RR, Ho KY, Sullivan CE. Effect of octreetide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Int Med 1994; 121: 478.
14. Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Int Med 1992; 117: 719-726.
15. Rajasoorja C, Holdaway IM, Wrightson P, Scott DJ, Iddertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102.
16. Melmed S. Acromegaly New Engl J Med 1990; 322: 966-977
17. Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991; 72: 245-249.
18. Daughday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1-4.
19. Prager D, Hsiao-Lin L, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor 1 receptor mutant. Proc Natl Acad Sci USA 1994; 91: 2181-2185
20. Brunner JE, Johnson CC, Zafar S, et al. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol 1990; 32: 65-71.
21. Murphy LJ, Bell GI, Friesen HG. Growth hormone stimulates sequential induction of c-inyc and insulin like growth actor I expression in vivo. Endocrinology 1987; 120: 1806-1812.
22. Moon HD, Li CH, Simpson ME. Effect of pituitary hormones on carcinogenesis with 9,10-dimethyl-1,2 dibenzanthacene in hypophysectomized rats. Cancer Res 1956; 16: 111-116.
23. Akaza H, Matsuki K, Matsushima H, Koiso K, Aso Y. Stimulatory effects of growth hormone on rat bladder carcinogenesis. Cancer 1991; 68: 24: 2418-2421.
24. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth transgenic mice created from two different strains of mice. J Steroid Biochem Molec Biol 1992; 43: 1-3.
25. Underwood LE. The risks of growth hormone therapy: does growth hormone influence tumor formation or tumor growth? In: Frisch H, Thoerner M, eds. Hormonal Regulation of Growth. New York: Raven Press, 1989; 231-239.
26. Lamberts S, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1992; 12: 450-482.
27. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JJ. Acromegaly and gastrointestinal cancer. Cancer 1991; 68: 1673.
28. Klein I, Parveen G, Gavaler JS, Van Thiel DH. Colonie polyps in patients with acromegaly. Ann Intern Med 1982; 97; 27-30.
29. Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol (Oxf) 1990; 32: 65-71.
30. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-299.
31. Roth J. Treatment with growth hormone focus on specificity with a view to the future. In: Blackman MR, Harman SM, Roth J, Shapiro JR, eds. GHRH, GH, and IGF-I: Basic and Clinical Advances. New York Springer-Verlag, 1995; pp 291-298.